For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study. People with type 2 ...

Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...